Table 1 Interleukin-17F expression in cancer
From: Variable roles of interleukin-17F in different cancers
Cancer | Sample and cancer type | Target | Method | Patients + control | Main findings | Authors |
|---|---|---|---|---|---|---|
Bladder | Surgical resection | Protein | IHC | 80 (bladder cancer) + 23 (cystitis) + 6 (hyperplastic bladder polyps) | IL-17F was overexpressed in the bladder cancer group (p < 0.01) | Liu et al. 2016 [11] |
Breast | Blood | Protein | Multiplex | 150 + 60 | Soluble levels of IL-17F were similar between breast cancer patients and healthy control (data not shown) | Avalos-Navarro et al. 2019 [12] |
Surgical specimens | Protein | IHC | 180 | IL-17F was not associated with pCR rate but tumors with IL17F infiltrates were significantly smaller than those without them (P = 0.041). | Oda et al. 2012 [13] | |
Colorectal | Cultured rectal cancer biopsy | Protein | Multiplex ELISA | 12 (rectal cancer) + 8 (normal) | IL-17A/F was secreted at significantly higher levels from the rectal cancer secretome than the normal rectal secretome (p = 0.003). | Heeran et al. 2020 [14] |
CRC, surgical resection | Protein, mRNA | RT-qPCR, WB, IHC | 67 | IL-17F was overexpressed in CRC tumor tissues compared with paired non-tumor mucosa at both mRNA and protein levels. Overexpression of IL-17F was associated with worse RFS (p = 0.03) and OS (p < 0.05) | Chen et al., 2019 [15] | |
CRC, endoscopic biopsy | Protein | IHC | 29 (CRC) + 17 (UC) + 7 (CHP) | Positive IL-17F was significantly higher in UC and polyp samples compared with CRC (p = 0.00001 and p = 0.0007) | Liu et al. 2018 [16] | |
CRC, serum | Protein | Multiplex | 122 | No association between IL-17F and OS/PFS | Lereclus et al. 2017 [17] | |
CC, surgical resection, serum | Protein | Bio-Plex | 33 | Elevated levels of IL-17F were associated with advanced disease. Stage IV showed elevated systemic levels of IL-17F compared to stages I-III (p all< 0.05). | Sharp et al. 2017 [18] | |
CRC, serum | Protein | ELISA | 109 + 52 | No IL-17F was detected in patients’ sera and only one healthy individual had IL-17F in his serum. | Nemati et al. 2015 [19] | |
CRC, cultured surgical resection | Protein | IHC/IF | 10 + 10 | IL-17F was decreased in CRC compared to healthy control | Al-Samadi et al. 2015 | |
CC, surgical resection | Protein + mRNA | IHC, WB, RT-qPCR | 40 | Lower levels of IL-17F mRNA were found in cancer tissue compared to normal mucosa (p < 0.05) | Tong et al. 2012 [20] | |
Oral | Oral and/or oropharyngeal cancer, saliva | protein | ELISA | 71 | The higher salivary concentrations of IL-17F was significantly associated with disease advancement. | Zielińska et al. 2020 |
OTSCC, surgical resection | Protein | IHC/IF | 83 | Extracellular IL-17F at the tumor invasion front was associated with better disease-specific survival in patients with all-stages and early-stages of oral tongue SCC. (p = 0.001) | Almahmoudi et al. 2019 [21] | |
OSCC, blood | Protein | ELISA | 58 + 52 | IL-17F was decreased in OSCC patient samples compared to healthy control (p < 0.05). | Xiaonan et al. 2019 [22] | |
OSCC, serum | Protein | ELISA | 85 (OSCC) + 15 (leukoplakia) + 28 (healthy) | IL-17F was decreased in OSCC patient samples compared to healthy controls (p < 0.05). Patients with smoking habit had higher IL-17F. | Ding et al. 2015 [23] | |
Leukemia | CLL, blood | Protein | FCM | 21 + 9 | No significant association between TH17F cells and CLL | Sherry et al. 2015 [24] |
B-CLL, serum and cell lysates | Protein | WB, ELISA | 23 + 13 | IL-17F is less expressed in PMNs and B-lymphocytes of patients compared to cells of healthy subjects. IL-17F was significantly increased in serum of stage IV disease patients compared with healthy subjects and stage 0/I and III patients. | Garley et al., 2014 [25] | |
Liver | HCC, blood | Protein | Bio-Plex | 87 + 87 | IL-17F levels not associated with HCC | Shen et al. 2018 [26] |
HCV-HCC, surgical resection | mRNA | qRT-PCR | 40 (cancerous + adjacent non-cancerous tissues) | IL-17F positive frequency was higher in cancerous tissue than in non-cancerous tissue | Wu et al. 2017 [27] | |
Lung | surgical resection | Protein | IHC | 55 + 12 | Expression of IL-17F was positively associated with tumor differentiation and negatively associated with lymph node metastasis and TNM staging (p all< 0.05) | Li et al. 2019 [28] |
NSCLC, surgical resection | Protein | IHC | 29 (squamous cell carcinoma) + 30 (adenocarcinoma) + 10 (healthy control) | IL-17F immunoreactivity was increased in both SCC and ADC tissue compared with healthy control (p < 0.05). IL-17F immunoreactivity was expressed principally in macrophages, but also epithelial cells and some malignant cells. | Huang et al., 2018 [29] | |
NSCLC, serum | Protein | Multiplex | 50 + 14 | IL-17F was decreased in squamous cell carcinoma stage M1 compared to M0 (P < 0.05) and in stages IIIB-IV compared to stages I-IIIa (p < 0.01) | Yang et al. 2015 [30] | |
Lymphoma | BIA-ALCL, surgical resection | Protein | IHC | 4 (BIA-ALCL) + 4 (healthy) + 10 (LP) + 6 (pcALCL) | IL-17F expression was weaker in BIA-ALCL tumor cells | Kadin et al. 2016 [31] |
AIDS-NHL, serum | Protein + mRNA | multiplex immunoassay | 176 (AIDS-NHL) + 176 (HIV+) | No significant association between IL-17F expression and AIDS-NHL | Vendrame et al. 2014 [32] | |
CTCL, skin biopsy | mRNA | PCR | 60 | IL-17F was expressed more in progressive CTCL compared to non-progressive disease (p < 0.05) | Willerslev-Olsen et al. 2014 [33] | |
CTCL, surgical resection | mRNA | PCR | 60 | IL-17F+ patients had a significantly increased risk of disease progression (odds ratio = 2.75; p = 0.025) compared with IL-17F- patients | Krejsgaard et al. 2013 [34] | |
CTCL, surgical resection | mRNA | RT-qPCR | 21 (CTCL) + 5 (psoriasis) + 6 (normal) | IL17F mRNA levels were not significantly elevated in lesional skin of CTCL | Miyagaki et al. 2011 [35] | |
CTCL, surgical resection | mRNA | RT-PCR | 62 | IL-17F genes were expressed in poor prognosis clusters, and seemed to strongly correlate with an advanced and/or progressive disease | Litvinov et al. 2010 [36] | |
Ovarian | surgical resection | Protein | FCM | 24 (cystadenocarcinoma) + 25 (cystadenoma) + 11 (serous borderline tumors) + 20 (control) | Number of IL-17F-positive TH17 cells is not increased or decreased in ovarian cancer | Winkler et al. 2017 [37] |
ascites | Protein | Cytokine profiling kit | 266 | No association between IL-17F and OS | Chen et al. 2015 [38] | |
Pancreas | serum | Protein | Luminex | 78 (pancreatic adenocarcinoma) + 41 (control) + 40 (chronic pancreatitis) + 20 (recurrent acute pancreatitis) | IL-17F was decreased in pancreatic adenocarcinoma when compared with chronic pancreatitis (p = 0.023) | Park et al. 2020 [39] |
Prostate | surgical resection | Protein | IHC | 116 (prostate cancer) + 10 (BPH) | A significant higher IL-17F expression was found in the prostate cancer group in comparison to the BPH group (p < 0.05). | Janiczek et al. 2020 [40] |
surgical resection | Protein | IHC | 29 (prostate adenocarcinoma) + 47 (BPH) + 6 (control) | IL-17F was elevated in BPH (p = 0.014) and prostate adenocarcinoma (p = 0.026) compared to healthy controls. | Liu et al. 2015 [41] | |
Skin | Skin BCC, serum | Protein | ELISA | 81 + 53 | IL-17F levels not associated with cancer risk | Mohammadipour et al. 2019 [42] |